Business Description
Damora Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US36322Q2066
Share Class Description:
DMRA: Ordinary SharesTotal Employee Number:
7Description
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7836.75 | |||||
Equity-to-Asset | 0.96 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -37.3 | |||||
3-Year EPS without NRI Growth Rate | 59.6 | |||||
3-Year FCF Growth Rate | 51.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.61 | |||||
9-Day RSI | 64.71 | |||||
14-Day RSI | 63.28 | |||||
3-1 Month Momentum % | -24.58 | |||||
6-1 Month Momentum % | -16.2 | |||||
12-1 Month Momentum % | 464.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.48 | |||||
Quick Ratio | 22.48 | |||||
Cash Ratio | 22.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.9 | |||||
Shareholder Yield % | -15.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -149.8 | |||||
ROA % | -140.64 | |||||
ROIC % | -7205.23 | |||||
3-Year ROIIC % | 1618.17 | |||||
ROC (Joel Greenblatt) % | -69460.78 | |||||
ROCE % | -152.27 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.92 | |||||
Price-to-Tangible-Book | 4.92 | |||||
EV-to-EBIT | -8.63 | |||||
EV-to-Forward-EBIT | -16.53 | |||||
EV-to-EBITDA | -8.64 | |||||
EV-to-Forward-Revenue | 19.76 | |||||
EV-to-FCF | -82.93 | |||||
Price-to-Projected-FCF | 114.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.92 | |||||
| Price-to-Net-Cash | 3.67 | |||||
Earnings Yield (Greenblatt) % | -11.59 | |||||
FCF Yield % | -1.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DMRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Damora Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.68 | ||
| Beta | 1.6045 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 162.8 | ||
| 14-Day RSI | 63.28 | ||
| 14-Day ATR ($) | 2.579535 | ||
| 20-Day SMA ($) | 26.19325 | ||
| 12-1 Month Momentum % | 464.8 | ||
| 52-Week Range ($) | 2.45 - 38.3251 | ||
| Shares Outstanding (Mil) | 61.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Damora Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Damora Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 20 days | ||
| General meeting for 2026 | 2026-06-17 09:00 | 20.59 (+1.63%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 24.36 (+0.41%) | ||
| Annual report for 2025 | 2026-03-19 | 21.15 (-9.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 21.15 (-9.23%) | ||
| Guidance call for 2026 | 2026-03-09 10:40 | 28.91 (+2.12%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 5.94 (+2.41%) | ||
| Second quarter earnings results for 2025 | 2025-08-05 | 3.39 (+0.15%) | ||
| General meeting for 2025 | 2025-06-18 09:00 | 3.22 (+1.58%) |
Show
Entries
Damora Therapeutics Inc Frequently Asked Questions
What is Damora Therapeutics Inc(DMRA)'s stock price today?
The current price of DMRA is $30.95. The 52 week high of DMRA is $38.33 and 52 week low is $2.45.
When is next earnings date of Damora Therapeutics Inc(DMRA)?
The next earnings date of Damora Therapeutics Inc(DMRA) is 2026-08-05 Est..
Does Damora Therapeutics Inc(DMRA) pay dividends? If so, how much?
Damora Therapeutics Inc(DMRA) does not pay dividend.
Guru Commentaries on NAS:DMRA
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Galecto Inc, Actelis Networks, ShiftPixy, Alpha Teknova, or SeaStar Medical Holding? | 2023-09-28 |
Articles on Damora Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers